Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Li, Chenguang ^a,b,c   Hao, Ligang ^a,b,c   Li, Yue ^a,b,c   Wang, Shengguang ^a,b,c   Chen, Hui ^a,b,c   Zhang, Lianmin ^a,b,c   Ke, Bin ^a,b   Yin, Yuesong ^a,b,c   Suo, Haijin ^a,b,c,d   Sun, Bingsheng ^a,b,c   Zhang, Bin ^a,b,c   Wang, Changli ^a,b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c Tianjin Lung Cancer Center   (China)

^d Beichen Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TELOMERASE REVERSE TRANSCRIPTASE; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ALK GENE; ARTICLE; BRAF GENE; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HER2 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PROMOTER REGION; SOMATIC MUTATION; TERT GENE; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84910668607     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107276     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367-1380.
3. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.
4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246.
5. Pao W, Hutchinson KE (2012) Chipping away at the lung cancer genome. Nat Med 18: 349-351.
6. Li C, Fang R, Sun Y, Han X, Li F, et al. (2011) Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 6: e28204.
7. Cancer Genome Atlas Research N (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525.
8. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957-959.
9. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110: 6021-6026.
10. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339: 959-961.
11. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Jr., Curry JL, et al. (2013) Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119: 3821-3829.
12. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, et al. (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18: 1167-1176.
13. Perez-Moreno P, Brambilla E, Thomas R, Soria JC (2012) Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 18: 2443-2451.
14. Gold KA, Wistuba, II, Kim ES (2012) New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res 18: 3002-3007.
15. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, et al. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-870.
16. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, et al. (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370: 1189-1197.
17. Jeon JH, Kang CH, Kim HS, Seong YW, Park IK, et al. (2014) Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. Eur J Cardiothorac Surg.
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
19. Hurst CD, Platt FM, Knowles MA (2014) Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 65: 367-369.
20. Sun Y, Ren Y, Fang Z, Li C, Fang R, et al. (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28: 4616-4620.
21. Gao B, Sun Y, Zhang J, Ren Y, Fang R, et al. (2010) Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol 5: 1130-1135.